Human TSLP R (Luc) HEK293 Reporter Cell

产品评论
货号-规格
价格
Qty.
CHEK-ATF045-2Vials (1Vial X 2)
询价
Fiber-add-1piece
可选服务
询价
合计0件 产品金额¥ 0

产品信息

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required

描述(Description)

The Human TSLP R (Luc) HEK293 Reporter Cell was engineered to not only express STAT5 signaling response element, but also express the receptors full length human TSLP R (Gene ID: 64109) and IL-7 R alpha (Gene ID: 3575). When stimulated with human TSLP protein, the TSLP/TSLP R interaction drives STAT5-mediated luminescence. Inhibition of TSLP binding to TSLP R by either anti-TSLP or anti-TSLP R antibodies results in a decrease in luminescence.

应用说明(Application)

Screen for anti-human TSLP or anti-human TSLP R neutralizing antibody

IL-7 R alpha & TSLP R Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Zeocin (100 μg/mL) + Puromycin (2 μg/mL)

培养基(Complete Growth Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

产品数据图

 

Receptor Assay

IL-7 R alpha & TSLP R FACS

Co-expression analysis of human TSLP R and IL-7 R alpha on Human TSLP R (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human TSLP R (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-TSLP R antibody and FITC-labeled anti-IL-7 R alpha antibody.

Protocol

 

Application

IL-7 R alpha & TSLP R APPLICATION

Inhibition of human TSLP protein-induced reporter activity by anti-human TSLP neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human TSLP protein (Cat. No. TSP-H52Hb) with a final concentration of 0.3 μg/mL. The EC50 of anti-human TSLP neutralizing antibody is approximately 0.55 μg/mL.

Protocol

 

Signaling Bioassay

IL-7 R alpha & TSLP R SIGNALING

Response to human TSLP protein (RLU).
The Human TSLP R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (Cat. No. TSP-H52Hb). The EC50 was approximately 0.1392 μg/mL.

Protocol

IL-7 R alpha & TSLP R SIGNALING

Response to human TSLP protein (Fold).
The Human TSLP R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (Cat. No. TSP-H52Hb). The max induction fold was approximately 45.15

Protocol

 

Passage Stability

IL-7 R alpha & TSLP R PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human TSLP R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein. Human TSLP protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-26.

Protocol

 
 

产品评论
发表评论

背景

Thymic stromal lymphopoietin (TSLP) is a pleiotropic cytokine and takes multi-functions via binding to a high-affinity heteromeric complex composed of thymic stromal lymphopoietin receptor (TSLPR) chain and IL-7Rα. The receptor complex on cells co-expressing TSLPR and IL-7Rα activated downstream genes expression and initiate proinflammatory signaling. TSLP involved in a variety of allergic diseases (e.g., atopic dermatitis, bronchial asthma). Further investigation indicated that TSLP is also involved in chronic inflammatory (i.e., chronic obstructive pulmonary disease and celiac disease) and autoimmune (e.g., psoriasis, rheumatoid arthritis) disorders and several cancers.

前沿进展

 
靶点信息
  • 英文全称:

    Interleukin-7 receptor subunit alpha

  • 中文全称:

    白细胞介素-7受体α亚基

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    9 详情

  • 最高研发阶段:

    临床二期

数据表和文档
联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品信息
  • 产品数据图
  • 产品评论
  • 背景